Drugs / C21
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 missed | ||||||
| Phase 1 | NCT05831644 | Mar → Jun 2023 | type 2 diabetes mellitus | Vicore Pharma AB | Completed | Missed primary |
| Phase 1 | NCT05830799 | Mar → May 2023 | — | Vicore Pharma AB | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT04533022 | Nov 2020 → Mar 2024 | idiopathic pulmonary fibrosis | Vicore Pharma AB | Completed | No outcome recorded |
| Phase 2 | NCT04452435 | Jul → Oct 2020 | COVID-19 | Vicore Pharma AB | Completed | No outcome recorded |
| Phase 2 | NCT04388176 | Jan → Dec 2020 | Raynaud disease, systemic sclerosis | Vicore Pharma AB | Completed | Missed primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT04880642 | Sep 2021 → Apr 2022 | COVID-19 | Vicore Pharma AB | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C21 | “C21, single dose, oral administration twice daily, for 15 days” NCT05830799 ↗ |
| Known as | Buloxibutid, Compound 21 | “Buloxibutid, Compound 21” NCT04533022 ↗ |
| Action | Activate | “a selective angiotensin II type 2 receptor agonist” PMID 35894657 ↗ Feb 2023 |
| Route | Oral | “single oral dose of C21 (200 mg)” PMID 35894657 ↗ Feb 2023 |